<?xml version="1.0" encoding="UTF-8"?>
<p id="Par4">The purified inactivated Zika vaccine (PIZV) has previously been evaluated in mouse models and was immunogenic in AG129 and CD1 mice and protected AG129 mice against lethal ZIKV challenge
 <sup>
  <xref ref-type="bibr" rid="CR16">16</xref>
 </sup>. In those studies, Baldwin 
 <italic>et al</italic>. demonstrated that neutralizing antibodies correlate with protection in AG129 mice. PIZV is currently being evaluated for safety and immunogenicity in phase 1 trials (ClinicalTrials.gov NCT03343626).
</p>
